Hartmann Wellhoefer MD

Hartmann Wellhoefer joined the Shire now part of Takeda in 2012 and leads Takeda’s Global Medical Affairs function for the Rare Metabolic Disease portfolio including Fabry, Gaucher, Hunter Disease as well as Hypoparathyroidism and several associated pipeline compounds.

With over 20 years of experience in the pharmaceutical industry, Dr. Wellhoefer has worked in a variety of roles including drug target evaluation, business development, clinical development, life cycle management (LCM), global access to medicines and medical affairs in global, regional and local functions in Europe and the United States.

Hartmann Wellhoefer has an MD from Technical University, Munich, Germany, and trained in Internal Medicine at Rechts der Isar, University Hospital also in Munich.